Y-mAbs Therapeutics, Inc (NASDAQ:YMAB)

35.01
Delayed Data
As of Jul 31
 -0.70 / -1.95%
Today’s Change
14.16
Today|||52-Week Range
50.49
+12.03%
Year-to-Date

Stock Price Forecast

The 9 analysts offering 12-month price forecasts for Y-mAbs Therapeutics, Inc have a median target of 48.00, with a high estimate of 52.00 and a low estimate of 40.00. The median estimate represents a +37.10% increase from the last price of 35.01.

Analyst Recommendations

The current consensus among 10 polled investment analysts is to Buy stock in Y-mAbs Therapeutics, Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past
months for detail

 
 
 
 
 
 
 
 

Earnings and Sales Forecasts

Current Quarter

Earnings per Share
-$0.69
Sales
$0.00
Reporting Date
Aug 12

Earnings per Share

Move your mouse over a quarter or year to see how estimates have changed over time.

Growthquarterly -4.92%
 
 
 
 
 
 
Growthannually -12.66%
 
 
 
 

Sales

Growthquarterly --
Growthannually --
 
 
 
 
Key to the earnings and sales forecast charts.